SAN DIEGO, March 31 /PRNewswire/ -- AndroScience Corporation today announced that it has been chosen to present at "The 21st Annual CONNECT Financial Forum" on April 14th.
AndroScience (http://www.androscience.com/) is one of a select group of high-caliber growth companies invited to participate in the annual conference sponsored by CONNECT, which is widely regarded as the nation's most successful regional program linking very-early-stage high-technology and life science entrepreneurs with the resources they need for success. This premier investment forum provides VC and private-equity investors, institutional and hedge funds, and technology executives an early look at many of the most exciting companies in Southern California.
"We're delighted to be presenting at this prestigious event, which will attract an estimated 300 high tech and life sciences investors, entrepreneurs, and high-level executives. This conference gives us high-level exposure to future funding sources as well as potential strategic partnerships," noted Charles Shih PhD CEO and Andrew Loh PhD COO of AndroScience Corporation. "The exposure to blue-chip funding entities is priceless."
According to Duane Roth, Executive Director of CONNECT, "The CONNECT Financial Forum continues to bridge the gap between promising companies and capital providers. It's an ideal way for start-ups to get exposure and engage a roomful of venture capitalists and potential investors. In turn, capital providers gain access to pre-screened companies with commercially viable technologies, all in a single day."
The program will be held on April 14th, 2005 at Sheraton Harbor Island -- West Tower, San Diego. For more information on attending or accessing presenting company profiles, please go to http://www.connect.org/
AndroScience has recently discovered and patented a family of compounds derived from natural products that selectively enhance the degradation of the androgen receptor, preventing androgen from exerting its unwanted functions on acne, and promoting prostate cancer cell growth. These compounds do not affect the endogenous androgens, testosterone or dihydrotestosterone(DHT). This appears to be a novel and unique mechanism of action. They are efficacious both topically and systemically as demonstrated in animal models. An IND and Phase 1/2 Clinical Trials for dermal application in acne is planned beginning in 2006 with alopecia trials to follow. Other compounds are being developed for prostate cancer, BPH, and wound healing.
Andrew Loh PhD, COO 858-638-7230, 858-401-0578(cell) aloh@androscience.com
AndroScience CorporationCONTACT: Andrew Loh PhD, COO of AndroScience Corporation,+1-858-638-7230, or cell, +1-858-401-0578, aloh@androscience.com
Web site: http://www.connect.org/
Web site: http://www.androscience.com/
